Clinical Research Division, Fred Hutch
Dr. Evan Ya-Wen Yu is a medical oncologist who treats patients with prostate, bladder and testicular cancer at Seattle Cancer Care Alliance, Fred Hutch’s clinical-care partner. He also serves as the Clinical Trials Core director of Genitourinary Medical Oncology at SCCA. As a physician-scientist, he provides a personalized-medicine approach to test novel therapies and discover unique cancer biomarkers. Dr. Yu also has a background in basic science; as a researcher he studies the biological mechanisms of drug sensitivity and treatment resistance. His interests also include cancer biomarkers, imaging (PET and MRI scans) and bone health. His overall goal is to discover novel biomarkers that can help guide treatment and aid in the development of novel treatments for prostate cancer.
Assistant Professor, Oncology
University of Washington School of Medicine
M.D., University of Washington, 1998
B.S., University of Washington, Zoology, 1994
Dr. Yu is currently in collaboration with Dr. David Mankoff of Nuclear Medicine, evaluating PET scans in with novel radiotracers as a marker of treatment response for patients with metastatic prostate cancer. He is also studying the role of Fatty Acid Synthase as it relates to 11C-acetate PET uptake and prostate cancer biology.
Dr. Yu has plans for multiple PET studies in the future that evaluate bone and even image the androgen receptor. He is testing multiple novel agents in prostate cancer that target multiple kinases, survivin, and clusterin (anti-apoptotic protein).
Study Number: RG1003872
Study Number: 20162991
Study Number: 20172434
Study Number: RG1003438